J
Jana M. Ellegast
Researcher at Harvard University
Publications - 21
Citations - 2736
Jana M. Ellegast is an academic researcher from Harvard University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 9, co-authored 16 publications receiving 2466 citations. Previous affiliations of Jana M. Ellegast include Broad Institute & University of Zurich.
Papers
More filters
Journal ArticleDOI
5'-Triphosphate RNA Is the Ligand for RIG-I
Veit Hornung,Jana M. Ellegast,Sarah Kim,Krzysztof Brzózka,Andreas Jung,Hiroki Kato,Hendrik Poeck,Shizuo Akira,Karl-Klaus Conzelmann,Martin Schlee,Stefan Endres,Gunther Hartmann +11 more
TL;DR: It is demonstrated that the 5′-triphosphate end of RNA generated by viral polymerases is responsible for retinoic acid–inducible protein I (RIG-I)–mediated detection of RNA molecules in viruses known to be detected by MDA-5 such as the picornaviruses.
Journal ArticleDOI
Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice
Yasuyuki Saito,Yasuyuki Saito,Jana M. Ellegast,Anahita Rafiei,Yuanbin Song,Daniel Kull,Mathias Heikenwalder,Mathias Heikenwalder,Anthony Rongvaux,Anthony Rongvaux,Stephanie Halene,Richard A. Flavell,Richard A. Flavell,Markus G. Manz +13 more
TL;DR: In this paper, the authors transplanted mobilized peripheral blood (PB) CD34+ cells in sublethally irradiated newborn and adult recipients and found that the transplanted PB cells showed higher engraftment levels in bone marrow, spleen, and PB in newborn transplanted MSTRG/MISTRG as compared with nonobese diabetic/severe combined immunodeficient Il2rg-/- or human SIRPα-transgenic Rag2-/-Il2rg+/- recipients.
Journal ArticleDOI
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Ninel Azoitei,Christopher M. Hoffmann,Jana M. Ellegast,Claudia R. Ball,Kerstin Obermayer,Ulrike Gößele,Britta Koch,Katrin Faber,Felicitas Genze,Mark Schrader,Hans A. Kestler,Hartmut Döhner,Gabriela Chiosis,Hanno Glimm,Stefan Fröhling,Claudia Scholl +15 more
TL;DR: HSP90 inhibition depletes STK33 in KRAS mutant tumors in KRas mutant tumors and results in down-regulation of HSP90 activity in these patients with KRAS mutated tumors.
Journal ArticleDOI
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
S. Rudat,S. Rudat,Anja Pfaus,Ya-Yun Cheng,Ya-Yun Cheng,J. Holtmann,Jana M. Ellegast,C. Bühler,Daniela Di Marcantonio,Esteban Martínez,Stefanie Göllner,Claudia Wickenhauser,Carsten Müller-Tidow,Christoph Lutz,Lars Bullinger,Michael D. Milsom,Stephen M. Sykes,Stefan Fröhling,Stefan Fröhling,Claudia Scholl +19 more
TL;DR: The results indicate that RET-mTORC1 signaling promotes AML through autophagy suppression, suggesting that targeting RET or, more broadly, depletion of leukemogenic drivers via Autophagy induction provides a therapeutic opportunity in a relevant subset of AML patients.
Journal ArticleDOI
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2
Jonathan R. LaRochelle,Michelle Fodor,Jana M. Ellegast,Xiaoxi Liu,Vidyasiri Vemulapalli,Morvarid Mohseni,Travis Stams,Sara J. Buhrlage,Kimberly Stegmaier,Matthew J. LaMarche,Michael G. Acker,Stephen C. Blacklow +11 more
TL;DR: This work employs high-throughput screening to discover a lead chemical scaffold, the benzothiazolopyrimidones, that allosterically inhibits this oncogenic phosphatase by simultaneously engaging the C-SH2 and PTP domains.